Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy

Archive ouverte

Diamantopoulou, Zoi | Gilles, Maud-Emmanuelle | Sader, Maha | Cossutta, Mélissande | Vallée, Benoît | Houppe, Claire | Habert, Damien | Brissault, Blandine | Leroy, Eric | Maione, Federica | Giraudo, Enrico | Destouches, Damien | Penelle, Jacques | Courty, José | Cascone, Ilaria

Edité par CCSD ; Impact journals -

International audience. In this study, a novel anticancer reagent based on polyplexes nanoparticles was developed. These nanoparticles are obtained by mixing negatively charged polyelectrolytes with the antitumour cationically-charged pseudopeptide N6L. Using two in vivo experimental tumor pancreatic models based upon PANC-1 and mPDAC cells, we found that the antitumour activity of N6L is significantly raised via its incorporation in polyplexed nanoparticles. Study of the mechanism of action using affinity isolation and si-RNA experiments indicated that N6L-polyplexes are internalized through their interaction with nucleolin. In addition, using a very aggressive model of pancreatic cancer in which gemcitabine, a standard of care for this type of cancer, has a weak effect on tumour growth, we observed that N6L-polyplexes administration has a stronger efficacy than gemcitabine. Biodistribution studies carried out in tumour-bearing mice indicated that N6L-polyplexes localises in tumour tissue, in agreement with its antitumour effect. These results support the idea that N6L nanoparticles could develop into a promising strategy for the treatment of cancer, especially hard-to-treat pancreatic cancers.

Suggestions

Du même auteur

Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature

Archive ouverte | Gilles, Maud-Emmanuelle | CCSD

International audience. Pancreatic cancer is a highly aggressive tumor, mostly resistant to the standard treatments. Nucleolin is overexpressed in cancers and its inhibition impairs tumor growth. Herein, we showed t...

Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression

Archive ouverte | Ponzo, Matteo | CCSD

International audience. Background: The pancreatic ductal adenocarcinoma (PDAC) microenvironment is highly fibrotic and hypoxic, with poor immune cell infiltration. Recently, we showed that nucleolin (NCL) inhibitio...

Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma

Archive ouverte | Raineri, Fabio | CCSD

International audience. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and resistant cancer with no available effective therapy. We have previously demonstrated that nucleolin targeting by N6L impair...

Chargement des enrichissements...